Marksans Pharma Limited
NSE: MARKSANS · Pharmaceuticals · sector
₹296.65NSE close 2026-10-26
Key numbers
Market cap₹13,443 cr
Price₹296.65
52w high / low₹351 / ₹155
P/E26.0xSector median 27.9x
P/B4.4xSector median 2.9x
Book value₹66.7
Dividend yield0.27%Sector median 0.48%
ROE31.6%Sector median 11.7%
ROCE23.4%Sector median 12.3%
OPM22.5%Sector median 14.0%
Debt / equity0.01xSector median 0.16x
EV/EBITDA17.5xSector median 18.6x
Interest cover28.6x
Current ratio5.17x
Sales growth 3y+16.8%Sector median +9.6%
Profit growth 3y+16.4%Sector median +13.3%
PEG2.01x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹990 cr vs borrowings ₹30 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 28.6x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 4 of the last 5 years (FY25, FY24, FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 20% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹296.65 on 2026-10-26: -15.5% from the 52-week high, +91.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹348.40 · low ₹160.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 642 | 682 | 71 | 620 | 720 | 754 | 856 | 841 |
| EBITDA | 136 | 139 | 13 | 100 | 144 | 161 | 195 | 213 |
| OPM % | 21.1% | 20.4% | 17.8% | 16.1% | 20.1% | 21.3% | 22.8% | 25.3% |
| Other income | 11 | 28 | 2 | 6 | 22 | 20 | 35 | 25 |
| Net profit | 97 | 105 | 9 | 58 | 98 | 113 | 148 | 157 |
| EPS (₹) | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 |
| Revenue YoY | +12.2% | +10.6% | +1,108.3% | +35.6% | ||||
| Profit YoY | +1.6% | +8.3% | +1,533.2% | +169.5% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,491 | 1,852 | 2,177 | 262 | 2,951 | 3,172 |
| EBITDA | 259 | 339 | 459 | 53 | 601 | 714 |
| Net profit | 187 | 265 | 343 | 38 | 418 | 517 |
| EPS (₹) | 4.51 | 6.41 | 6.92 | 8.40 | 9.22 | 11.41 |
| Revenue growth | +24.2% | +17.6% | -88.0% | +1,025.1% | +57.4% | |
| Profit growth | +42.0% | +29.1% | -88.8% | +992.3% | +92.3% | |
| Dividend / share (₹) | 0.25 | 0.25 | 0.50 | 0.60 | 0.80 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +16.8% | +16.5% | +57.4% |
| Net profit | +16.4% | +11.9% | +92.3% |
| EPS | +12.9% | +9.9% | – |
| Share price | – | +4.3% (2y) | +65.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 1,745 | 2,065 | 247 | 3,023 |
| Borrowings | – | 42 | 29 | 2 | 30 |
| Cash & equivalents | – | 716 | 701 | 70 | 990 |
| Total assets | – | 2,190 | 2,681 | 324 | 3,861 |
| Fixed assets | – | 380 | 676 | 58 | 625 |
| Capital work in progress | – | 7 | 5 | 1 | 15 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 417 | 453 | 54 | 645 |
| Inventory | – | 485 | 618 | 85 | 972 |
| Payables | – | 231 | 268 | 31 | 337 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 99 | 237 | 230 | 21 | 458 |
| Cash from investing | -42 | -259 | -141 | -5 | -248 |
| Cash from financing | 80 | 198 | -69 | -7 | -71 |
| Capex | 46 | 54 | 209 | 17 | 131 |
| Free cash flow | 53 | 184 | 22 | 3 | 328 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 15.2% | 16.6% | 15.5% | 13.8% |
| ROCE % | – | 19.4% | 20.8% | 20.7% | 19.2% |
| Debtor days | – | 82 | 76 | 75 | 80 |
| Inventory days | – | 192 | 217 | 270 | 278 |
| Payable days | – | 91 | 94 | 98 | 96 |
| Cash conversion cycle (days) | – | 183 | 199 | 247 | 262 |
| Working capital days | – | 263 | 247 | 240 | 272 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 43.87% |
| FIIs | 19.06% |
| DIIs | 5.54% |
| of which Mutual funds | 3.72% |
| Public (non-institutions) | 31.53% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| Promoter group | % |
|---|---|
| Mark Saldanha | 43.80% |
| Schenelle Megan Saldanha | 0.03% |
| Sandra Saldanha | 0.02% |
| Merrill Jean Saldanha | 0.01% |
| Marise Ann Saldanha | 0.00% |
| Public holders above 1% | % |
|---|---|
| Orbimed Asia IV Mauritius Fvci Limited | 8.62% |
| Uti-healthcare Fund | 1.66% |
2,47,508 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MARKSANS | ₹13,443 cr | 26.0x | 4.4x | 31.6% | 23.4% | 22.5% | +16.8% | 0.27% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-20 | Dividend | Dividend - Re 0.90 Per Share |
| 2025-08-01 | Dividend | Dividend - Re 0.80 Per Share |
| 2024-09-17 | Dividend | Dividend - Rs 0.60 Per Share |
| 2023-06-07 | Dividend | Dividend - Re 0.50 Per Share |
| 2022-08-19 | Dividend | Annual General Meeting/Dividend - Rs 0.25 Per Share |
| 2021-09-15 | Dividend | Annual General Meeting/Dividend - Rs 0.25 Per Share |
| 2021-07-01 | Other | Extra-Ordinary General Meeting |
| 2020-09-22 | Dividend | Annual General Meeting/Dividend - Rs 0.10 Per Share |
| 2019-09-19 | Dividend | Annual General Meeting/Dividend - Rs 0.05 Per Share |
| 2018-09-19 | Dividend | Annual General Meeting/Dividend Re 0.05 Per Share |
| 2017-09-19 | Dividend | Annual General Meeting/Dividend - Re 0.05 Per Share |
| 2016-09-22 | Dividend | Annual General Meeting/Dividend - Re 0.12 Per Share |
| 2015-09-23 | Dividend | Annual General Meeting/ Dividend - Re 0.12/- Per Share |
| 2014-09-18 | Dividend | Annual General Meeting / Dividend - Re 0.10/- Per Share |
| 2013-09-19 | Other | Annual General Meeting |
| 2012-09-20 | Other | Annual General Meeting |
| 2011-09-22 | Other | Annual General Meeting |
| 2010-09-22 | Other | Annual General Meeting |
| 2009-09-17 | Other | Annual General Meeting |
| 2008-09-23 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceutical Formulation: Research, manufacturing and sales of generics, specialty, OTC and Rx pharmaceutical products in pain management, upper respiratory, digestive, CVS, CNS, oncology, antidiabetics, anti-biotic, etc.
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MARKSANS |
| BSE code | 524404 |
| ISIN | INE750C01026 |
| Face value | ₹1.0 |
| Incorporated | 1992-12-16 |
| Website | www.marksanspharma.com |
| Plants (India / abroad) | 2 / 2 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.